Pulmonary Fibrosis Trial Met Primary Lung Function Goal
A 60mg dose of admilparant helped adults with idiopathic pulmonary fibrosis preserve lung function in a recent study.
Updated on Oct. 12, 2026 in Asthma
Live Poll
Do you trust pharmaceutical companies to deliver consistent long-term growth based on their latest trial news?
The Phase 3 ALOFT-IPF clinical trial found that 60mg of admilparant significantly slowed lung-function decline in 1,255 adults over 52 weeks. This trial provides new data for those managing idiopathic pulmonary fibrosis, though the higher 120mg dose did not meet the primary endpoint.
Why it matters
The study's results offer a potential new therapeutic path for patients struggling with the progression of this chronic lung condition. While the 60mg dose showed promise in clinical measurements, researchers are still evaluating the broader implications for long-term treatment protocols.
In the 52-week ALOFT-IPF Phase 3 trial of 1,255 adults, the 60mg dose of admilparant reached statistical significance in slowing the decline of forced vital capacity compared to a placebo. The 120mg dose did not achieve statistical significance, and discontinuation rates were similar across all groups.
The players
Bristol Myers Squibb
A global biopharmaceutical company focused on discovering and developing innovative medicines for serious diseases including lung fibrosis.
The details
The study measured changes in forced vital capacity, a primary indicator of lung health, from baseline to the 52-week mark. Participants were randomized to receive either the drug or a placebo to observe how the intervention affects the rate at which lung function declines over time. Researchers are continuing to analyze why the 60mg dose was effective while the 120mg dose did not meet the primary endpoint criteria.
Timeline
2024 Q1: Bristol Myers Squibb reported a net loss of $11.911bn.
2026 Q2: The company reported net income of $3.317bn.
September 30, 2026: The short-sale ratio was measured at 0.669.
October 9, 2026: The short-sale ratio decreased to 0.294.
Early 2027: Topline results for the ALOFT-PPF trial are expected.
Health Landscape
This clinical trial finding sits within the ongoing development of treatments for idiopathic pulmonary fibrosis, an area where researchers are actively seeking to stabilize lung function. Bristol Myers Squibb continues this research effort as they anticipate topline data from the ALOFT-PPF trial in early 2027.
Patients currently managing idiopathic pulmonary fibrosis should discuss these trial results with their pulmonologist to understand how evolving research might influence future treatment options. It is important to wait for formal clinical guidance from your physician before considering any changes to your care plan based on preliminary trial milestones.
The takeaway
The ALOFT-IPF trial highlights the potential for new pharmacological interventions to impact the trajectory of lung function decline. Patients should continue to track their respiratory symptoms and coordinate with their care team to monitor for updates on new treatment protocols.
What happens next
Detailed trial results are expected to be presented at a future medical meeting, and topline results for the ALOFT-PPF trial are expected in early 2027.
Further reading
For more on managing complex lung conditions and ongoing research, explore the Asthma section.
Live Poll
Do you trust pharmaceutical companies to deliver consistent long-term growth based on their latest trial news?
